| Autor: |
Borges MC; MRC Integrative Epidemiology Unit at the University of Bristol United Kingdom.; Population Health Sciences Bristol Medical School University of Bristol United Kingdom., Schmidt AF; Institute of Cardiovascular Science University College London London United Kingdom.; Groningen Research Institute of Pharmacy University of Groningen the Netherlands.; Division Heart and Lungs Department of Cardiology University Medical Center Utrecht Utrecht The Netherlands., Jefferis B; UCL Department of Primary Care & Population Health UCL Medical School London United Kingdom., Wannamethee SG; UCL Department of Primary Care & Population Health UCL Medical School London United Kingdom., Lawlor DA; MRC Integrative Epidemiology Unit at the University of Bristol United Kingdom.; Population Health Sciences Bristol Medical School University of Bristol United Kingdom., Kivimaki M; Department of Epidemiology and Public Health University College London London United Kingdom., Kumari M; Department of Epidemiology and Public Health University College London London United Kingdom.; Institute for Social and Economic Research University of Essex United Kingdom., Gaunt TR; MRC Integrative Epidemiology Unit at the University of Bristol United Kingdom.; Population Health Sciences Bristol Medical School University of Bristol United Kingdom., Ben-Shlomo Y; Population Health Sciences Bristol Medical School University of Bristol United Kingdom., Tillin T; Cardiometabolic Phenotyping Group Institute of Cardiovascular Science University College London London United Kingdom., Menon U; MRC Clinical Trials Unit at UCL Institute of Clinical Trials & MethodologyUniversity College London London United Kingdom., Providencia R; Farr Institute of Health Informatics University College London London United Kingdom.; Barts Heart Centre St Bartholomew's Hospital Barts Health NHS Trust London United Kingdom., Dale C; Farr Institute of Health Informatics University College London London United Kingdom., Gentry-Maharaj A; MRC Clinical Trials Unit at UCL Institute of Clinical Trials & MethodologyUniversity College London London United Kingdom., Hughes A; Institute of Cardiovascular Science University College London London United Kingdom., Chaturvedi N; Institute of Cardiovascular Science University College London London United Kingdom., Casas JP; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) VA Boston Healthcare System Boston MA USA., Hingorani AD; Institute of Cardiovascular Science University College London London United Kingdom.; Farr Institute of Health Informatics University College London London United Kingdom. |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of the American Heart Association [J Am Heart Assoc] 2020 Mar 03; Vol. 9 (5), pp. e013131. Date of Electronic Publication: 2020 Mar 02. |
| DOI: |
10.1161/JAHA.119.013131 |
| Abstrakt: |
Background We aimed at investigating the association of circulating fatty acids with coronary heart disease (CHD) and stroke risk. Methods and Results We conducted an individual-participant data meta-analysis of 5 UK-based cohorts and 1 matched case-control study. Fatty acids (ie, omega-3 docosahexaenoic acid, omega-6 linoleic acid, monounsaturated and saturated fatty acids) were measured at baseline using an automated high-throughput serum nuclear magnetic resonance metabolomics platform. Data from 3022 incident CHD cases (13 104 controls) and 1606 incident stroke cases (13 369 controls) were included. Logistic regression was used to model the relation between fatty acids and odds of CHD and stroke, adjusting for demographic and lifestyle variables only (ie, minimally adjusted model) or with further adjustment for other fatty acids (ie, fully adjusted model). Although circulating docosahexaenoic acid, but not linoleic acid, was related to lower CHD risk in the fully adjusted model (odds ratio, 0.85; 95% CI, 0.76-0.95 per standard unit of docosahexaenoic acid), there was evidence of high between-study heterogeneity and effect modification by study design. Stroke risk was consistently lower with increasing circulating linoleic acid (odds ratio for fully adjusted model, 0.82; 95% CI, 0.75-0.90). Circulating monounsaturated fatty acids were associated with higher CHD risk across all models and with stroke risk in the fully adjusted model (odds ratio, 1.22; 95% CI, 1.03-1.44). Saturated fatty acids were not related to increased CHD risk in the fully adjusted model (odds ratio, 0.94; 95% CI, 0.82-1.09), or stroke risk. Conclusions We found consistent evidence that linoleic acid was associated with decreased risk of stroke and that monounsaturated fatty acids were associated with increased risk of CHD. The different pattern between CHD and stroke in terms of fatty acids risk profile suggests future studies should be cautious about using composite events. Different study designs are needed to assess which, if any, of the associations observed is causal. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text